study effect of azithromycin and doxycycline in mucus producing and inflammatory signaling pathways of allergic asthma

Asthma is a respiratory disease; involving millions of people worldwide. the main cause of asthma is allergy and immune response dysregulation. the effects of azithromycin and doxycycline as asthma-controlling drugs were evaluated in this study. mice asthma model was produced and asthmatic mice were treated with azithromycin (75 mg/kg, orally) and doxycycline (20 mg/kg, orally). eosinophils and neutrophils count, interleukin (il)-4, il-5, il-12, il-13, and total immunoglobulin e (ige) levels were measured. histological study and evaluation of the gene’s expression of muc5ac, muc5b, il-33, cox2, myd88, and traf6 were performed. azithromycin and doxycycline did not affect eosinophil and neutrophil percentage, il-4, il-5, il-12, total ige levels, peribronchial and perivascular inflammation, goblet cell hyperplasia, and gene expression of myd88, traf6, and cox2. treatment with azithromycin significantly decreased il-13 level, mucus secretion, and gene expression of il-33, muc5ac, and muc5b; compared to the non-treated asthma group. azithromycin administration controls mucus secretion and inflammation. azithromycin therapy and not doxycycline might be an effective adjuvant option in asthma by reducing mucus in the airway.